Medications for Pdgfraassociated Chronic Eosinophilic Leukemia
4 results
Imatinib mesylate (imatinib mesylate)
(IMATINIB MESYLATE)Camber Pharmaceuticals, Inc.
Usage: This drug is indicated for treating newly diagnosed Philadelphia positive chronic myeloid leukemia (Ph+ CML), acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome/chronic eosinophilic leukemia, dermatofibrosarcoma protuberans, and Kit+ gastrointestinal stromal tumors (GIST).
Imatinib mesylate (imatinib mesylate)
(Imatinib Mesylate)BluePoint Laboratories
Usage: This drug is indicated for newly diagnosed or treatment-resistant Philadelphia chromosome positive chronic myeloid leukemia, acute lymphoblastic leukemia in adults and pediatrics, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors in adults.
Imatinib mesylate (imatinib mesylate)
(imatinib mesylate)Wockhardt USA LLC.
Usage: This drug is indicated for newly diagnosed Philadelphia positive chronic myeloid leukemia (Ph+ CML), Ph+ CML in blast crisis or after interferon failure, adult relapsed/refractory Philadelphia positive acute lymphoblastic leukemia, myelodysplastic/myeloproliferative diseases with PDGFR rearrangements, aggressive systemic mastocytosis without D816V c-Kit mutation, hypereosinophilic syndrome, and unresectable dermatofibrosarcoma protuberans.
Imatinib mesylate (imatinib mesylate)
(Imatinib Mesylate)American Health Packaging
Usage: This drug is indicated for newly diagnosed Philadelphia positive chronic myeloid leukemia (CML) in chronic phase, Ph+ CML in various phases post-interferon therapy, relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL) in adults, and newly diagnosed Ph+ ALL in pediatric patients, among other specific malignancies.